Form 10-Q - Quarterly report [Sections 13 or 15(d)]:
SEC Accession No. 0000950170-25-072607
Filing Date
2025-05-15
Accepted
2025-05-15 16:06:58
Documents
70
Period of Report
2025-03-31

Document Format Files

Seq Description Document Type Size
1 10-Q rntx-20250331.htm   iXBRL 10-Q 1522527
2 EX-31.1 rntx-ex31_1.htm EX-31.1 17278
3 EX-31.2 rntx-ex31_2.htm EX-31.2 17514
4 EX-32.1 rntx-ex32_1.htm EX-32.1 8436
5 EX-32.2 rntx-ex32_2.htm EX-32.2 8427
  Complete submission text file 0000950170-25-072607.txt   7563813

Data Files

Seq Description Document Type Size
6 XBRL TAXONOMY EXTENSION SCHEMA WITH EMBEDDED LINKBASES DOCUMENT rntx-20250331.xsd EX-101.SCH 1263983
73 EXTRACTED XBRL INSTANCE DOCUMENT rntx-20250331_htm.xml XML 1164108
Mailing Address 12407 N. MOPAC EXPY. SUITE 250 #390 AUSTIN TX 78758
Business Address 12407 N. MOPAC EXPY. SUITE 250 #390 AUSTIN TX 78758 7378021989
Rein Therapeutics, Inc. (Filer) CIK: 0001420565 (see all company filings)

EIN.: 134196017 | Fiscal Year End: 1231
Type: 10-Q | Act: 34 | File No.: 001-38130 | Film No.: 25952843
SIC: 2834 Pharmaceutical Preparations
(CF Office: 03 Life Sciences)